SecBot SecBot
8-K ·Filed Apr 6, 2026

INGN

Inogen Inc
NEUTRAL
Impact 6/10
Horizonweeks Processed6mo ago SEC0001193125-26-143703
8-K material event: Items 1.01
Actionable Insight • Neutral

Traders should monitor for further changes in board composition or strategy, as activist involvement often leads to additional governance changes. The appointment of an experienced medtech executive suggests a focus on operational improvements.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
INGN ▼ -2.94% at T+60d
NEUTRAL call -2.94% · α vs SPY -16.21% · entry $6.80 → $6.60
Entry = T+0 close
Apr 6, 2026
via day close
T+1d
-1.91%
call -1.91% · α -4.45%
$6.67
settled 7mo ago
T+5d
-6.76%
call -6.76% · α -12.09%
$6.34
settled 7mo ago
T+20d
+2.50%
call +2.50% · α -7.28%
$6.97
settled 6mo ago
T+60d
-2.94%
call -2.94% · α -16.21%
$6.60
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Inogen Inc. has entered into a cooperation agreement with activist investor Kent Lake Partners, resulting in the appointment of Vafa Jamali to the board as an independent director. This follows shortly after the departure of another executive, indicating a forced management transition driven by investor pressure.

Key Facts

  • Inogen entered a cooperation agreement with Kent Lake Partners LP, Kent Lake PR LLC, and Benjamin Natter.
  • Vafa Jamali was appointed to the board as a Class I director and to the Audit and Compliance Committees.
  • The agreement includes a voting commitment from the investor parties to support board recommendations and customary standstill provisions.
  • This board appointment follows within 14 days of a prior executive departure, indicating a forced management transition.
  • The company will reimburse the investor parties for up to $7,500 in legal and related expenses.

Financial Impact

The financial impact is minimal, limited to a $7,500 reimbursement for investor expenses and standard director compensation for the new appointee.

expensescompensation

Risk Factors

  • Potential for further activist demands or board changes
  • Possible strategic shifts that could disrupt current operations

Market Snapshot

Exchange
Nasdaq
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-143703
Document: ingn-20260406.htm0001193125-26-143703
Document: ingn-ex99_1.htm0001193125-26-143703
Document: 0001193125-26-143703-index-headers.html0001193125-26-143703
Document: 0001193125-26-143703-index.html0001193125-26-143703
Document: 0001193125-26-143703.txt0001193125-26-143703
3 reports for INGN
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for INGN — sortable, filterable
TypeNow
Jun 11, 2026
19w ago
8-K
NEUTRAL ★ 3/10
$6.40 $5.23▼ −18.28%▼ −21.55%$7.18 (+12.19%)
Apr 6, 2026
29w ago
8-K
NEUTRAL ★ 6/10
$6.80 $6.60▼ −2.94%▼ −16.21%$7.18 (+5.59%)
Feb 24, 2026
34w ago
8-K
BULLISH ★ 7/10
$6.01 $6.34▲ +5.49%▼ −1.46%$7.18 (+19.47%)
Showing 3 of 3

US Market Status

Market Open — Closes in 1h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 6, 2026